Literature DB >> 9397989

Chromosomal aberrations in hepatocellular carcinomas: relationship with pathological features.

U Zimmermann1, D Feneux, G Mathey, F Gayral, D Franco, P Bedossa.   

Abstract

Fluorescence in situ hybridization performed on tissue sections can reveal chromosomal abnormalities related to histopathological features. This technique was performed on serial frozen sections from seven normal livers and 29 hepatocellular carcinomas (HCCs) using pericentromeric repeat-specific probes for chromosomes 1, 4, 6, 7, 8, 16, and 17. For each HCC and each probe, the percentage of cells showing one, two, or more than two signals was counted and compared with the distribution in the normal liver. According to these results, HCCs were categorized as monosomic, disomic, or polysomic (more than two signals) for the chromosome tested. These data were compared with the main histopathological characteristics of HCC. Chromosome gains were very common, preferentially affecting chromosome 1 (23 of 27 cases, 85%), chromosome 16 (16 of 27 cases, 59%), chromosome 7 (16 of 29 cases, 55%), chromosome 6 (15 of 29 cases, 52%) and chromosome 8 (14 of 29 cases, 48%). Monosomy was seen more rarely, affecting preferentially chromosome 16 (19%), chromosome 17 (14%), and chromosome 4 (10%). A significant correlation was observed between aneusomy of chromosome 4 and tumor size (P < .05) or the presence of vascular embolism (P < .05). In conclusion, chromosomal gains are frequent genetic events in human HCC. A significant association between a gain in chromosome 4 and large tumor size or vascular embolism suggests that this genetic abnormality is a late event in liver carcinogenesis.

Entities:  

Mesh:

Year:  1997        PMID: 9397989     DOI: 10.1053/jhep.1997.v26.pm0009397989

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  6 in total

1.  A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma.

Authors:  Vincent W Keng; Augusto Villanueva; Derek Y Chiang; Adam J Dupuy; Barbara J Ryan; Ilze Matise; Kevin A T Silverstein; Aaron Sarver; Timothy K Starr; Keiko Akagi; Lino Tessarollo; Lara S Collier; Scott Powers; Scott W Lowe; Nancy A Jenkins; Neal G Copeland; Josep M Llovet; David A Largaespada
Journal:  Nat Biotechnol       Date:  2009-02-22       Impact factor: 54.908

2.  Chromosomal abnormalities determined by comparative genomic hybridization are helpful in the diagnosis of atypical hepatocellular neoplasms.

Authors:  Sanjay Kakar; Xin Chen; Coral Ho; Lawrence J Burgart; Oyedele Adeyi; Dhanpat Jain; Viabhav Sahai; Linda D Ferrell
Journal:  Histopathology       Date:  2009-08       Impact factor: 5.087

3.  Impact of MACC1 on human malignant glioma progression and patients' unfavorable prognosis.

Authors:  Carsten Hagemann; Steffen Fuchs; Camelia M Monoranu; Pia Herrmann; Janice Smith; Tim Hohmann; Urszula Grabiec; Almuth F Kessler; Faramarz Dehghani; Mario Löhr; Ralf-Ingo Ernestus; Giles H Vince; Ulrike Stein
Journal:  Neuro Oncol       Date:  2013-11-11       Impact factor: 12.300

4.  Metastasis-associated in colon cancer 1 is a novel survival-related biomarker for human patients with renal pelvis carcinoma.

Authors:  Hailong Hu; Dawei Tian; Tao Chen; Ruifa Han; Yan Sun; Changli Wu
Journal:  PLoS One       Date:  2014-06-20       Impact factor: 3.240

5.  Onco-proteogenomics identifies urinary S100A9 and GRN as potential combinatorial biomarkers for early diagnosis of hepatocellular carcinoma.

Authors:  Chun-Hao Huang; Chao-Jen Kuo; Shih-Shin Liang; Shu-Wen Chi; Edward Hsi; Chi-Chao Chen; King-Teh Lee; Shyh-Horng Chiou
Journal:  BBA Clin       Date:  2015-03-03

6.  Genetic variation in ABCB5 associates with risk of hepatocellular carcinoma.

Authors:  Idy C-Y Leung; Charing C-N Chong; Tan T Cheung; Philip C Yeung; Kelvin K-C Ng; Paul B-S Lai; Stephen L Chan; Anthony W-H Chan; Patrick M-K Tang; Siu T Cheung
Journal:  J Cell Mol Med       Date:  2020-08-11       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.